[Skip to Content]
[Skip to Content Landing]
Viewpoint
April 2016

Adjuvant Bone-Targeted Therapies for Postmenopausal Breast Cancer

Author Affiliations
  • 1Academic Unit of Clinical Oncology, Weston Park Hospital, University of Sheffield, Sheffield, United Kingdom
JAMA Oncol. 2016;2(4):423-424. doi:10.1001/jamaoncol.2015.5768

Breast cancer commonly spreads to bone in a process influenced by the genetic signature of the tumor cells and a plethora of host cells interacting with growth factors within the bone microenvironment. Clinically overt bone metastases are incurable and may result in skeletal complications from bone fragility caused by tumor cell–activated osteoclastic bone resorption. To combat this, antiresorptive therapies, including bisphosphonates, are routinely used in the setting of bone metastasis and have effectively prevented most of its skeletal complications.1

First Page Preview View Large
First page PDF preview
First page PDF preview
×